Literature DB >> 10913405

Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle.

L R Armstrong1, E J Preston, M Reichert, D L Phillips, R Nisenbaum, N W Todd, I N Jacobs, A F Inglis, S C Manning, W C Reeves.   

Abstract

The incidence and prevalence of recurrent respiratory papillomatosis (RRP) for children aged <18 years were estimated in 2 US cities, Atlanta and Seattle, in 1996. All otolaryngologists in a 24-county area in metropolitan Atlanta (101 physicians) and an 8-county area in metropolitan Seattle (139 physicians) agreed to participate in the study. Medical record chart abstraction was performed only for children with documented current residence in the study area (21 patients in Atlanta and 14 patients in Seattle). The incidence rate for juvenile RRP was 1.11/100,000 population in Atlanta and 0.36/100, 000 in Seattle. The prevalence rate was 2.59/100,000 population in Atlanta and 1.69/100,000 in Seattle. In neither city did prevalences differ significantly when stratified by sex or race. Extrapolation of these estimates to the US population suggests that 80-1500 incident cases and 700-3000 prevalent cases of juvenile RRP will occur in the United States during 1999.

Entities:  

Mesh:

Year:  2000        PMID: 10913405     DOI: 10.1086/313914

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

Review 1.  Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.

Authors:  Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

3.  Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.

Authors:  Eddie A James; James A DeVoti; David W Rosenthal; Lynda J Hatam; Bettie M Steinberg; Allan L Abramson; William W Kwok; Vincent R Bonagura
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

Review 4.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

Review 5.  The economic burden of noncervical human papillomavirus disease in the United States.

Authors:  Delphine Hu; Sue Goldie
Journal:  Am J Obstet Gynecol       Date:  2008-05       Impact factor: 8.661

6.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

7.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

Authors:  James A DeVoti; Bettie M Steinberg; David W Rosenthal; Lynda Hatam; Andrea Vambutas; Allan L Abramson; Mark J Shikowitz; Vincent R Bonagura
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

Review 8.  Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.

Authors:  Anna R Giuliano; Guillermo Tortolero-Luna; Elena Ferrer; Ann N Burchell; Silvia de Sanjose; Susanne Kruger Kjaer; Nubia Muñoz; Mark Schiffman; F Xavier Bosch
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

9.  Multicenter initiative seeking critical genes in respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Craig S Derkay; Suzanne M Leal; Joseph Donfack; Garth D Ehrlich; J Christopher Post
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

10.  HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis.

Authors:  Colin M Gelder; O Martin Williams; Keith W Hart; Siôn Wall; Gareth Williams; Duncan Ingrams; Peter Bull; Mike Bunce; Ken Welsh; Sara E F Marshall; Leszek Borysiewicz
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.